Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a widespread diagnosis that affects many children and adolescents’ ability to function and succeed in academics, socially, or other situations. Non-stimulant medications have become widely utilized in this population, especially in stimulant-resistant individuals, whether due to poor efficacy or intolerance of side effects. However, these, too, harbor their own side effect profiles, including cardiovascular and sleep or energy level disturbances.
Objectives: We review the literature in discussion of the presentation and management of these adverse events for non-stimulant medications for ADHD, with a particular focus on atomoxetine and alpha agonists guanfacine and clonidine.
Conclusion: Non-stimulants are for the most part well tolerated but monitoring for cardiac and sleep difficulty is warranted.
Keywords: Mental health, children and adolescents, psychopharmacology, ADHD, attention deficit disorder, atomoxetine, alpha agonists.
Graphical Abstract
Related Journals
Current Drug Safety
Current Neuropharmacology
Current Pharmaceutical Design
Current Pharmaceutical Analysis
Current Vascular Pharmacology
CNS & Neurological Disorders - Drug Targets
Current Molecular Pharmacology
Adolescent Psychiatry
Current Drug Research Reviews
Current Psychiatry Research and Reviews
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
34
10
2
1